Drug Profile


Alternative Names: Lamivudine/zidovudine/nevirapine; Nevirapine/lamivudine/zidovudine; Nevirapine/zidovudine/lamivudine; Zidovudine/lamivudine/nevirapine; Zidovudine/nevirapine/lamivudine

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duquesne University
  • Developer Elim Pediatric Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 01 Jun 2013 Lamivudine/nevirapine/zidovudine may be available for partnering.
  • 01 Sep 2012 The US FDA informs Elim Pediatric Pharmaceuticals that it should submit separate New Drug Applications under the 505(b) pathway for the tablet and granule formulations of lamivudine/nevirapine/zidovudine
  • 30 Apr 2012 Elim Pediatric Pharmaceuticals completes a phase I trial in healthy volunteers in Nigeria (NCT01469520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top